In patients with both AF and type 2 diabetes, SGLT2 inhibitors were associated with a lower risk of either hospitalization for HF or mortality compared to DPP4 inhibitors, which may suggest that SGLT2 inhibitors may be considered as the first-line antidiabetic medication in patients with AF and diabetes. This evidence concerns the gene SLC5A2 and atrial fibrillation.